Alerta

尿中ｕＣ５ｂ－９検出に基づく局所補体阻害を介した補体媒介性疾患の標的治療

Resumen de: AU2024292030A1

Provided is the use of urinary C5b-9 (uC5b-9) as a highly accurate and superior biomarker well correlated with complement activity in local tissues affected by complement-mediated diseases (e.g., those with a kidney damage component). The biomarker is useful, for example, in treating and/or monitoring such complement-mediated diseases, using complement inhibitors targeted to such local tissues affected by the diseases, without systemic complement inhibition.

抗菌ペプチド

Resumen de: MX2026000543A

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.

一种靶向焦谷氨酸Aβ的单域抗体及其制备方法和应用

Resumen de: CN122444868A

0001 本发明具体涉及一种靶向焦谷氨酸Aβ的单域抗体及其制备方法和应用，所述单域抗体的氨基酸序列SEQ ID NO.1或SEQ ID NO.2或SEQ ID NO.3或SEQ ID NO.4或SEQ ID NO.5或SEQ ID NO.6 或SEQ ID NO.7或SEQ ID NO.8所示；以条纹斑竹鲨作为免疫对象，采用PE‑Aβ为抗原进行免疫，提取免疫鲨鱼外周血细胞的总RNA，逆转录为cDNA，以cDNA为模板进行扩增，与噬菌粒载体构建重组噬菌粒载体，转入感受态细胞中，扩大培养，筛选阳性克隆，得到所述单域抗体。本发明提供的单域抗体，能够特异性识别PEAβ，具有良好的结合活性，且分子量小，解决了目前尚未有靶向PEAβ的鲨鱼纳米抗体的技术问题，为后续研究该抗体在PEAβ的检测中的应用奠定了重要基础，具有开发检测PEAβ的试剂或治疗PEAβ相关疾病的药物的应用前景。

COMPOSITION FOR DETECTING AND DELIVERING COPPER IONS COMPRISING CARBON NANOPARTICLES

Resumen de: KR20260115290A

0001a 본 발명은 구리 이온 탐지 및 전달을 위한 탄소 나노입자에 관한 것으로 구체적으로는 황이 탄소와 섞여 있어 구리 이온을 탐지할 수 있고, 구리 이온을 내부에 포집하고 있어 생체 내로 구리 이온을 전달할 수 있는 나노입자에 관한 것이다.

C/EBPβ和/或CXCL10作为靶点在脓毒症相关脑病的诊断与治疗中的应用

Resumen de: CN122440826A

本发明公开了一种C/EBPβ和/或CXCL10作为靶点在脓毒症相关脑病的诊断与治疗中的应用，涉及生物医学领域。本发明首次揭示了一条在脓毒症相关脑病中驱动神经炎症与认知损伤的新信号通路：转录因子C/EBPβ通过直接结合并激活CXCL10的转录，进而诱导小胶质细胞发生NLRP3炎性小体介导的焦亡。焦亡的小胶质细胞释放大量炎症因子，导致神经元突触损伤与凋亡，最终引发认知功能障碍。基于此，本发明提出了将C/EBPβ和CXCL10作为治疗SAE的药物靶点（如开发其抑制剂或中和抗体）以及作为辅助诊断SAE的生物标志物的全新用途，为SAE的防治提供了新的策略和工具。

一种检测神经丝轻链蛋白的抗体及其应用

Resumen de: CN122444867A

本发明公开了检测神经丝轻链蛋白的抗体及其应用，具体涉及检测神经丝轻链蛋白的抗体和试剂盒，基于该抗体及试剂盒能够准确的检测神经丝轻链蛋白的存在。

一种试剂盒及RNF40在制备检测类风湿关节炎相关帕金森病产品中的应用

Resumen de: CN122445789A

0001 一种试剂盒及RNF40在制备检测类风湿关节炎相关帕金森病产品中的应用，该试剂盒包含用于特异性检测RNF40基因或蛋白表达水平的检测组分。本发明基于大规模人群队列分析、孟德尔随机化研究、多组织转录组筛选及动物共病模型体内功能验证，首次发现RNF40在类风湿关节炎与帕金森病关联轴上呈现双向介导特征，类风湿关节炎患者外周血等样本中RNF40表达水平显著低于参考值时，其发生帕金森病的风险增高。该试剂盒通过体外无创检测实现类风湿关节炎患者帕金森病风险的分层评估，还可通过连续监测RNF40表达变化进行动态预警，具有操作简便、适于大规模筛查的特点，为临床早期干预和精准管理提供了可靠工具。

一种磷酸化蛋白p-Tau217的吖啶酯抗体标记方法及其应用

Resumen de: CN122449140A

本发明公开了一种吖啶酯标记复合物，包括本体，标记于本体上的标记基团，所述本体为抗体，所述标记基团为吖啶酯类基团。一种吖啶酯标记复合物制备方法，包括以下步骤：吸取标记缓冲液至离心管中；吸取待标记的抗体至离心管中并混匀，生成第一混合溶液；加入吖啶酯溶液并混匀，在25℃下避光反应2小时，生成第二反应溶液；加入终止缓冲液并混匀，在25℃下避光反应30分钟，生成第三反应溶液；对第三反应溶液进行脱盐纯化，生成第四混合溶液；将第四混合溶液用0.22μm滤膜进行过滤，生成吖啶酯标记复合物。本发明的制备方法，吖啶酯与抗体的标记效率更高，反应性更强；非特异性吸附更低，灵敏度更高，重复性和稳定性更好，且标记方法简单快速易重复。

健康状態および疾患状態を監視および診断するための方法および組成物

Resumen de: WO2021127549A1

Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.

Collaborative artificial intelligence method and system

Resumen de: AU2026205405A1

A method for operating a virtual assistant, the method comprising: at an electronic device: initiating a virtual assistant operable to connect a user with one or more repositories of health information; identifying, by the virtual assistant, the user based on one or more user-specific features; associating a subset of the health information with the user based on the identification of the user, at least a portion of the subset of the health information relating to a particular subject; responsive to receiving a user input via the virtual assistant: accessing, by the virtual assistant, the one or more repositories of information; identifying one or more documents within the one or more repositories as being relevant to the user input; extracting partial response data from the one or more documents; processing, by the virtual assistant, the partial response data in view of the user input to generate a complete response to the user input; and providing the complete response for broadcasting via an output device associated with the electronic device, wherein the steps of identifying one or more documents within the one or more repositories as being relevant to the user input and extracting partial response data from the one or more documents include: identifying at least one parameter in the user input; identifying at least one intent associated with the user input, the at least one intent selected from a pool of intents identified from a plurality of intents based on the at leas

GENE THERAPIES FOR LYSOSOMAL DISORDERS

Resumen de: US20260209718A1

0000 The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.

COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY

Resumen de: US20260207789A1

0000 The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Resumen de: US20260209329A1

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.

BRAWNIN AGONISTS FOR USE IN THE TREATMENT OF AXONAL METABOLIC DISORDERS

Resumen de: US20260210943A1

Using primary mouse neuronal cultures and mouse models, the present inventors have highlighted the role of a new effector, BRAWNIN, in neuronal metabolic balance and cortical axon branching. The present inventors have shown that BRAWNIN expression is necessary and sufficient for cortical axon branching. The present inventors have particularly demonstrated that BRAWNIN expression allows completely restoring impaired axon branching phenotypes in an impaired axon development mouse model. The present invention therefore pertains to a BRAWNIN agonist for use in the treatment of axonal metabolic disorders. The present invention further pertains to screening methods for the identification of novel therapeutic compounds based on BRAWNIN expression in a cellular model.

Single-domain antibodies directed against gasdermin D and their use

Resumen de: US20260209323A1

The present invention is concerned with single-domain antibodies directed against gasdermin D (GSDMD). The single-domain antibodies can be used in medical applications, preferably for preventing and/or treating an inflammatory disease or condition in a subject, and/or for determining the presence or absence of GSDMD oligomers in a sample obtained from a subject.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Resumen de: AU2025226972A1

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.

METHOD TO DETECT AND TREAT PERIPHERAL NEUROPATHY

Resumen de: US20260210976A1

Disclosed herein is a kit to detect and determine post-synaptic density protein-95 (PSD-95) levels in subjects with peripheral neuropathy. Also disclosed herein, is a method of treating or preventing neuropathy in a subject. The method comprises detecting PSD-95 levels in a sample from the subject, using the kit disclosed herein and when the PSD-95 level differs from a control, the subject is treated for neuropathy.

IMPROVED PEPTIDE INHIBITORS OF P53 BINDING PROTEIN 53BP1

Resumen de: US20260207777A1

0000 Compositions and methods are provided for enhancing homology-directed repair in gene-editing applications using improved inhibitors of 53BP1.

METHODS OF PROGNOSIS FOR HEMORRHAGIC TRANSFORMATION FOLLOWING ENDOVASCULAR TREATMENT

Resumen de: US20260210974A1

Methods are provided for classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome following endovascular treatment (EVT) in an individual suffering from an acute ischemic stroke with respect to development of hemorrhagic transformation (HT). The data and integrated model provided herein demonstrates a pre-operative assessment of single-cell biomarkers for accurate prediction of HT following EVT in individuals suffering from acute ischemic strokes. The integrated model incorporates “immune features” such as activation of signaling proteins and/or the frequency of specific cell subset(s). The analysis and prediction of HT is used to guide therapeutic approaches to EVT and the post-treatment care. Specifically, the level of certain features (e.g. elevated prpS6 in memory Th1 CD4+T cells, elevated pCREB in naïve Th1 CD4+T cells and increased frequency of non-classical monocytes) demonstrate an increased likelihood of HT occurring following EVT.

METHODS FOR CLASSIFYING, DETECTING AND TREATING BIOLOGICAL DISEASES

Resumen de: AU2024399715A1

The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.

B-ISOXAZOLE DERIVATIVES, DIAGNOSTIC COMPOSITIONS; AND METHODS RELATED THERETO

Resumen de: AU2024401251A1

The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.

HIGH DENSITY MICROARRAYS AND USES THEREOF

Resumen de: US20260210959A1

The present disclosure relates to high density microarrays, methods of manufacturing the arrays, and uses thereof. In particular, the present disclosure provides high density microarrays of biological molecules that allow for specific and sensitive biological assays.

SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE

Resumen de: US20260210977A1

The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.

DIAGNOSIS AND TREATMENT OF LONG-COVID

Resumen de: US20260210975A1

0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.

SYSTEMS AND METHODS FOR IDENTIFYING GPCR MODULATORS AND OTHER AGENTS

Nº publicación: US20260210961A1 23/07/2026

Solicitante:

PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
CAMBRIDGE ENTERPRISE LTD [GB]
President and Fellows of Harvard College
Cambridge Enterprise Limited

Resumen de: US20260210961A1

0000 System and methods for identifying agents (e.g., proteins, peptides) that modulate G-protein coupled receptors (GPCRs) are generally described. For some embodiments, the agent is a nanobody that modulates the GPCR and may either act as an agonist (e.g., activate) or antagonist (e.g., deactivate) to the GPCR.